ERG

ERG Full Name

v-ets avian erythroblastosis virus E26 oncogene homolog

ERG Introduction

ERG encodes a transcription factor that belongs to the erythroblast transformation-specific (ETS) family, one of the largest families of transcriptional regulators. Since its initial identification as a human oncogene homologous to the v-ets oncogene of the avian erythroblastosis virus E26, ERG has emerged as a critical player in both normal physiological processes and multiple disease states. This gene presents a fascinating duality in human pathology—it functions as a potent oncogene in cancers such as prostate cancer and Ewing's sarcoma, while recently discovered germline mutations reveal its role as a tumor suppressor in bone marrow failure syndromes. Understanding ERG's multifaceted nature is essential for comprehending its contributions to development, hematopoiesis, and malignancy.

Figure 1. Strcuture of CD8A ERG.

Expression Pattern
ERG exhibits a remarkably restricted expression pattern in normal tissues, primarily limited to cells of endothelial and hematopoietic lineages. During embryonic development, ERG is expressed in mesodermal tissues including endothelial cells, mesenchymal condensations during precartilaginous deposition, and urogenital regions. In adult tissues, ERG protein is predominantly detected in vascular endothelial cells, specific hematopoietic cells, and transiently in pre-cartilage. Within the hematopoietic compartment, ERG is expressed during early T-cell development, in early pre-B cells, and continues to be expressed in mature B cells. Importantly, ERG is not detected in normal prostate epithelium, making its aberrant expression in prostate cancer a tumor-specific event of significant clinical utility. At the subcellular level, ERG localizes primarily to the nucleus, where it functions as a transcriptional regulator, though it can also be detected in the cytoplasm and associated with chromatin.

ERG exemplifies the complexity of transcription factor biology, serving essential roles in vascular and hematopoietic development while simultaneously acting as a potent oncogene in multiple human cancers. Its recent identification as a tumor suppressor in germline disorders adds another layer to its multifaceted nature. The gene's restricted expression pattern, involvement in recurrent chromosomal translocations, and tissue-specific functions make it an attractive therapeutic target. Understanding how the same gene can promote or suppress malignancy depending on context—somatic mutation versus germline alteration, fusion partner, cellular environment—remains a fundamental challenge with direct implications for developing ERG-targeted therapies in oncology and regenerative medicine.

Alternate Names for ERG

ERG; v-ets avian erythroblastosis virus E26 oncogene homolog; p55; erg-3; transcriptional regulator ERG; ets-related; TMPRSS2/ERG fusion; v-ets erythroblastosis virus E26 oncogene like; v-ets erythroblastosis virus E26 oncogene homolog; v-ets avian erythroblastosis virus E26 oncogene related

• Immunohistochemistry Antibodies for Pathology
• Immunohistochemistry Antibodies for Pathology